# Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

> **NCT01137071** · PHASE2 · TERMINATED · sponsor: **Recepta Biopharma** · enrollment: 29 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** Monoclonal antibody Hu3S193

## Key facts

- **NCT ID:** NCT01137071
- **Lead sponsor:** Recepta Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Total number of pts expected to be enrolled would not be met.
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137071, "Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01137071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*